After Jasper Therapeutics (JSPR) reported preliminary data from the company’s ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism, the two most prevalent sub types of CIndU, Stifel says 120mg briquilimab showed “good responses,” but thinks the stock debate will focus on the serum tryptase signal, which wasn’t depleted to the same extent as Celldex’s (CLDX) barzolvolimab at higher dose. The firm, which thinks today’s data imply that a higher dose should “at least” support a Q8W regimen, and is “bullish” into CSU data due January 6 showcasing both 180mg and 240mg doses, keeps a Buy rating and $80 price target on Jasper shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Morning Movers: Longboard Pharmaceuticals surges following deal to be acquired
- Jasper Therapeutics repoirts data from its SPOTLIGHT study of briquilimab
- Jasper concerns driven by Celldex data ‘overdone,’ says Stifel
- Jasper announces Health Canada clearance of trial application of briquilimab
- Block, GE HealthCare initiated: Wall Street’s top analyst calls